Voyager Therapeutics
VYGR
47 hedge funds and large institutions have $146M invested in Voyager Therapeutics in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 6 closing their positions.
5% more capital invested
Capital invested by funds: $140M → $146M (+$6.9M)
0.2% more ownership
Funds ownership: 41% → 41.19% (+0.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 21
16% less funds holding
Funds holding: 56 → 47 (-9)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.72M |
| 2 |
BlackRock
New York
|
+$6.45M |
| 3 |
CC
Casdin Capital
New York
|
+$1.4M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$1.35M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$865K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$3.54M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.57M |
| 3 |
DM
Deerfield Management
New York
|
-$1.43M |
| 4 |
GC
Globeflex Capital
San Diego,
California
|
-$732K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$531K |
VYGR Hedge Fund Activity: Q1 2017 in Review
47 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q1 2017, worth a combined $146M — up 4.9% from $140M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of VYGR and 3 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 19 added.
The largest buyer was Adage Capital Partners, adding an estimated $6.72M. The largest seller was Goldman Sachs, cutting an estimated $3.54M.
- 47 institutional investors held Voyager Therapeutics (VYGR) as of Q1 2017, down from 56 in Q4 2016.
- Funds reported $146M of Voyager Therapeutics stock for Q1 2017, up 4.9% quarter-over-quarter.
- 3 funds opened new Voyager Therapeutics positions in Q1 2017 and 6 closed out, a net change of -3 holders.
- The largest Voyager Therapeutics buyer in Q1 2017 was Adage Capital Partners, an estimated $6.72M added.
- The largest Voyager Therapeutics seller in Q1 2017 was Goldman Sachs, an estimated $3.54M sold.
Based on aggregated 13F filings for Q1 2017.